Recombinant human hs

Journal of Allergy and Clinical Immunology

Volumn 130, Issue 4, 2012, Pages

  Wasserman, Richard L ^a,g   Melamed, Isaac ^b   Stein, Mark R ^c   Gupta, Sudhir ^d   Puck, Jennifer ^e   Engl, Werner ^f   Leibl, Heinz ^f   McCoy, Barbara ^f   Empson, Victoria G ^f   Gelmont, David ^g   Schiff, Richard I ^g  

^a Allergy/Immunology Research Center of North Texas   (United States)

^b 1st Allergy and Clinical Research Center ^*  (United States)

^c North Palm Beach   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f BAXTER INNOVATIONS GMBH   (Austria)

^g BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

Bioavailability Persons With Antibody Deficiency Require Lifelong Igg Replace; Efficacy; Facilitated Subcutaneous Immunoglobulin; Intravenous Immunoglobulin; Primary Immunodeficiency; Recombinant Human Hyaluronidase; Tolerability

Indexed keywords

ANTIBIOTIC AGENT; BACTERIUM ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN G; RECOMBINANT HYALURONIDASE; HYALURONOGLUCOSAMINIDASE; IMMUNOGLOBULIN; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BRONCHITIS; CHILD; CHILL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; FEMALE; FEVER; GENITAL EDEMA; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; INFECTION RATE; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; SCHOOL CHILD; SINUSITIS; STAPHYLOCOCCAL PNEUMONIA; VOMITING; CLINICAL TRIAL; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; HUMANS; HYALURONOGLUCOSAMINIDASE; IMMUNOGLOBULINS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFUSIONS, SUBCUTANEOUS; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS;

EID: 84869122138     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2012.06.021     Document Type: Article

References (35)

1. Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol 2010; 125(2 suppl 2):S182-94.
2. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol 2004;112:1-7.
3. Bonilla FA. Intravenous immunoglobulin: Adverse reactions and management. J Allergy Clin Immunol 2008;122:1238-9.
4. Meth MJ, Rosenthal DW, Bonagura VR. Subcutaneous immunoglobulin infusion to treat infants and toddlers with antibody deficiencies. Ann Allergy Asthma Immunol 2010;105:187-8.
5. Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: Advantages of the subcutaneous route. BioDrugs 2007;21:105-16.
6. Moore ML, Quinn JM. Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: Advancements into the 21st century. Ann Allergy Asthma Immunol 2008;101:114-21.
7. Misbah S, Sturzenegger MH, Borte M, Shapiro RS, Wasserman RL, Berger M, et al. Subcutaneous immunoglobulin: Opportunities and outlook. Clin Exp Immunol 2009;158(suppl 1):51-9.
8. Gustafson R, Gardulf A, Hansen S, Leibl H, Engl W, Linden M, et al. Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies. Clin Exp Immunol 2008;152:274-9.
9. Gardulf A, Nicolay U, Asensio O, Bernatowska E, Bock A, Carvalho BC, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies-a prospective multi-national study. J Clin Immunol 2006;26:177-85.
10. Jolles S, Sleasman JW. Subcutaneous immunoglobulin replacement therapy with Hizentra(R), the first 20% SCIG preparation: A practical approach. Adv Ther 2011;28:521-33.
11. Wasserman RL, Melamed I, Kobrynski L, Strausbaugh SD, Stein MR, Sharkhawy M, et al. Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. J Clin Immunol 2011;31:323-31.
12. Wasserman RL, Irani AM, Tracy J, Tsoukas C, Stark D, Levy R, et al. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/ chromatography purified in patients with primary immunodeficiency disease. Clin Exp Immunol 2010;161:518-26.
13. Wasserman RL, Melamed I, Nelson RP Jr, Knutsen AP, Fasano MB, Stein MR, et al. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. Clin Pharmacokinet 2011;50:405-14.
14. Frost GI. Recombinant human hyaluronidase (rHuPH20): An enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv 2007;4: 427-40.
15. Yocum RC, Kennard D, Heiner LS. Assessment and implication of the allergic sensitivity to a single dose of recombinant human hyaluronidase injection: A doubleblind, placebo-controlled clinical trial. J Infus Nurs 2007;30:293-9.
16. Harb G, Lebel F, Battikha J, Thackara JW. Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers. Curr Med Res Opin 2010;26:279-88.
17. Allen CH, Etzwiler LS, Miller MK, Maher G, Mace S, Hostetler MA, et al. Recombinant human hyaluronidase-enabled subcutaneous pediatric rehydration. Pediatrics 2009;124:e858-67.
18. Thomas JR, Yocum RC, Haller MF, von Gunten CF. Assessing the role of human recombinant hyaluronidase in gravity-driven subcutaneous hydration: The INFUSELR study. J Palliat Med 2007;10:1312-20.
19. Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, et al. Primary immunodeficiency diseases: An update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin Immunol 2007;20:776-94.
20. Al-Herz W, Bousfiha A, Casanova JL, Chapel H, Conley ME, Cunningham-Rundles C, et al. Primary immunodeficiency diseases: An update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency. Front Immunol 2011;2:54.
21. Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for Industry: Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (human) as Replacement Therapy for Primary Humoral Inmmunodeficiency. Washington, DC: US Department of Health and Human Services, Food and Drug Administration (FDA); 2008.
22. van Elteren PH. On the combination of independent two-sample tests of Wilcoxon. Bull Inst Int Stat 1960;37:351-61.
23. Church JA, Leibl H, Stein MR, Melamed IR, Rubinstein A, Schneider LC, et al. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin (IGIV 10%) in patients with primary immunodeficiency. J Clin Immunol 2006;26: 388-95.
24. Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M. Subcutaneous IgG Study Group. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006;26: 265-73.
25. Berger M, Murphy E, Riley P, Bergman GE. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. South Med J 2010;103:856-63.
26. Skoda-Smith S, Torgerson TR, Ochs HD. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease. Ther Clin Risk Manag 2010;6:1-10.
27. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin Immunol 2010;137:21-30.
28. Quinti I, Soresina A, Guerra A, Rondelli R, Spadaro G, Agostini C, et al. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: Results from a multicenter prospective cohort study. J Clin Immunol 2011;31:315-22.
29. Vivaglobin Immune Globulin Subcutaneous (Human) 16% Liquid [package insert]. Marburg, Germany: CSL Behring; 2010.
30. Hagan JB, Fasano MB, Spector S, Wasserman RL, Melamed I, Rojavin MA, et al. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol 2010;30:734-45.
31. Jolles S, Bernatowska E, De Gracia J, Borte M, Cristea V, Peter HH, et al. Efficacy and safety of Hizentra in patients with primary immunodeficiency after a doseequivalent switch from intravenous or subcutaneous replacement therapy. Clin Immunol 2011;141:90-102.
32. Gardulf A, Nicolay U, Asensio O, Bernatowska E, Bock A, Costa-Carvalho BT, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 2004;114: 936-42.
33. Bookbinder LH, Hofer A, Haller MF, Zepeda ML, Keller GA, Lim JE, et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release 2006;114:230-41.
34. Wynne C, Harvey V, Schwabe C, Waaka D, McIntyre C, Bittner B. Comparison of subcutaneous and intravenous administration of trastuzumab: A phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer. J Clin Pharmacol 2012 [Epub ahead of print].
35. Melamed I, McDonald A, Neff A, Beck A. An analysis of safety and tolerability data on 10%, 16%, and 20% formulations of subcutaneous immunoglobulins (SCIG) [abstract]. J Allergy Clin Immunol 2011;127(2 suppl 1):Abstract16.